INTERNATIONAL PATENT: UNIVERSITY OF MARYLAND, BALTIMORE FILES APPLICATION FOR "ANTI-HDGF ANTIBODY METHODS FOR OVERCOMING ACQUIRED RESISTANCE IN EGFR-TARGETED THERAPY OF LUNG CANCER"

GENEVA, Sept. 10 -- UNIVERSITY OF MARYLAND, BALTIMORE (620 W. Lexington Street4th FloorOffice of Research & DevelopmentBaltimore, Maryland 21201) filed a patent application (PCT/US2025/017770) for "ANTI-HDGF ANTIBODY METHODS FOR OVERCOMING ACQUIRED RESISTANCE IN EGFR-TARGETED THERAPY OF LUNG CANCER" on Feb 28, 2025. With publication no. WO/2025/184457, the details related to the patent application was published on Sep 04, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): REN, Hening (6490 River Clyde Dr.Highland, Maryland 20777)

Abstract: Targeted therapy using osimertinib (an EGFR tyrosine...